sagopilone (BAY86-5302)
/ Bayer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2013
Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer
(Lung Cancer)
- P2, N=128; Sponsor: Bayer; NCT00160069; “Eight patients across all arms had a confirmed partial response; the primary endpoint was not achieved. The most frequently reported adverse event (AE) was peripheral sensory neuropathy (75%). Most hematologic AEs were grade 1 or 2.”
P2 data • Non Small Cell Lung Cancer
1 to 1
Of
1
Go to page
1